Clinical trials: Diabetes Type I
Diabetes Mellitus, Obesity
A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of a single intravenous (through a vein) dose of trodusquemine (MSI-1436) in obese, type 2 diabetics.
- Trial name
- NCT00606112
- Testing
- Trodusquemine (MSI-1436)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Genaera Corporation
Diabetes Mellitus, Type 1
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin.
- Trial name
- NCT00575159
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this study was to investigate the total exposure of NN5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.
- Trial name
- NCT01138488
- Testing
- insulin degludec/insulin aspart
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
OPT101 in Type 1 Diabetes Patients
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
- Trial name
- NCT05428943
- Testing
- OPT101
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Op-T LLC
Type 1 Diabetes, Type 2 Diabetes
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
- Trial name
- NCT07864168
- Testing
- Next Generation Extended Wear Sensors
- Where
- 18 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic response (the effect of the investigated drug on the body) of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects…
- Trial name
- NCT01590836
- Testing
- insulin degludec, insulin degludec/insulin aspart
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- BEGIN™ (NCT01079234)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 82 sites in United States, Belgium and 5 more
- Volunteers
- 493 people
- Sponsor
- Novo Nordisk A/S
Diabetic Polyneuropathy
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
- Trial name
- NCT00878293
- Testing
- GRT6005, MS Continus®
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 90 people
- Sponsor
- Tris Pharma, Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in subjects with insulin requiring diabetes.
- Trial name
- NCT00604344
- Testing
- insulin detemir, insulin NPH
- Where
- Japan
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal
The addition of BioChaperone to already marketed prandial insulin analogue accelerates the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous…
- Trial name
- NCT02344992
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)
To determine the pharmacokinetic properties, safety and tolerability of single/multiple oral administration of Gemigliptin and Food effect in healthy Chinese subjects.
- Trial name
- NCT03864432
- Testing
- Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
- Trial name
- NCT00143247
- Testing
- Exubera® (inhaled insulin)
- Where
- 12 sites in United States
- Volunteers
- 173 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study.
- Trial name
- NCT03465878
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Canada, Germany
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin…
- Trial name
- NCT02536859
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Diabetes Mellitus, Type 1
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the…
- Trial name
- NCT01654380
- Testing
- LY2605541, Insulin glargine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
- Trial name
- PROTECT (NCT03875729)
- Testing
- teplizumab
- Where
- 62 sites in United States, Belgium and 7 more
- Volunteers
- 328 people
- Sponsor
- Provention Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.